ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia

EP. 1: Recent Guideline Updates in the Frontline Management of CLL

January 6th 2025

Dr Niemann provides an overview of the evolving treatment landscape of CLL.

EP. 2: Tailoring Treatment Approaches for Fit vs Unfit CLL Patients

January 8th 2025

A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.

EP. 3: Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients

January 15th 2025

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

EP. 4: Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data

January 24th 2025

Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.

EP. 5: Clinical Insights and Real-World Evidence

January 24th 2025

Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.